MedTrace Logo

European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)

NCT00214903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30597

Last updated 2014-12-01

Study results available
· View outcomes & findings →

Summary

The objective of the active surveillance study is to compare incidence rates of serious adverse events in users of all types of newly prescribed oral continuous combined HRT products. The primary focus is the assessment of pertinent cardiovascular outcomes (such as venous and arterial thromboembolism) in new HRT users for up to 8.5 years.

Conditions

  • Menopausal Symptoms

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Center for Epidemiology and Health Research, Germany

    lead OTHER

Principal Investigators

  • Juergen Dinger, MD, PhD · ZEG, Invalidenstrasse 115, 10115 Berlin, Germany

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2011-05-31
Completion
2011-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214903 on ClinicalTrials.gov